The global burden of asthma: executive summary of the GINA Dissemination Committee Report, Allergy, vol.59, issue.5, pp.469-478, 2004. ,
Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches, Nat Med, vol.18, issue.5, pp.716-741, 2012. ,
Targeting the interleukin pathway in the treatment of asthma, The Lancet, vol.386, issue.9998, pp.1086-1096, 2015. ,
Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma, Nature Medicine, vol.19, issue.8, pp.977-979, 2013. ,
Thérapies ciblées dans l?asthme sévère : À la découverte de nouvelles molécules, Revue des Maladies Respiratoires, vol.30, issue.8, pp.613-626, 2013. ,
Role of Biologics in Asthma, American Journal of Respiratory and Critical Care Medicine, vol.199, issue.4, pp.433-445, 2019. ,
Role of Biologics in Asthma, American Journal of Respiratory and Critical Care Medicine, vol.199, issue.4, pp.433-445, 2019. ,
L?asthme en France : synthèse des données épidémiologiques descriptives, Revue des Maladies Respiratoires, vol.27, issue.2, pp.151-159, 2010. ,
Updated guidelines (2015) for management and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of the Société de Pneumologie de Langue Française (SPLF) (Full length text), Revue des Maladies Respiratoires, vol.33, issue.4, pp.279-325, 2016. ,
Difficult-to-Treat Severe Asthma, GINA 2019 DIFFICULT-TO-TREAT & SEVERE ASTHMA in adolescent and adult patients, vol.119, pp.1337-1385, 2011. ,
The prevalence of severe refractory asthma, Journal of Allergy and Clinical Immunology, vol.135, issue.4, pp.896-902, 2015. ,
Severe asthma: definition and mechanisms, Allergy, vol.56, issue.9, pp.825-840, 2001. ,
P199 Adverse events profile of oral corticosteroids among asthma patients in the uk, External influences on asthma, 2017. ,
Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis, Respiratory Research, vol.19, issue.1, 2018. ,
inta, 07 ART7.pdf ,
,
Benralizumab (Fasenra) for Severe Eosinophilic Asthma, JAMA, vol.319, issue.14, p.1501, 2018. ,
,
Informations sur la santé à l'intention des migrants: plate-forme internet migesplus, PrimaryCare, vol.9, issue.01, pp.16-18, 2009. ,
External Validity of Randomized Controlled Trials in Severe Asthma, American Journal of Respiratory and Critical Care Medicine, vol.192, issue.2, pp.259-261, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01763173
Randomised controlled trials in severe asthma: selection by phenotype or stereotype, European Respiratory Journal, vol.53, issue.2, p.1802187, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02061533
Mepolizumab effectiveness and identification of super-responders in severe asthma, European Respiratory Journal, vol.55, issue.5, p.1902420, 2020. ,
Mepolizumab effectiveness and identification of super-responders in severe asthma, European Respiratory Journal, vol.55, issue.5, p.1902420, 2020. ,
Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis, BMC Pulmonary Medicine, vol.19, issue.1, p.176, 2019. ,
Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study, Cogent Medicine, vol.7, issue.1, 2020. ,
Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study, Cogent Medicine, vol.7, issue.1, p.1776468, 2020. ,
An experimental study of group opinion, Futures, vol.1, issue.5, pp.408-426, 1969. ,
Full Issue PDF Volume 40, Issue 11, Fisheries, vol.40, issue.11, pp.525-572, 2015. ,
,
Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility, Respiratory Medicine, vol.154, pp.69-75, 2019. ,
Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment, Allergy, vol.71, issue.9, pp.1335-1344, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01785638
Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment, Allergy, vol.71, issue.9, pp.1335-1344, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01785638
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma, Allergy, vol.74, issue.9, pp.1716-1726, 2019. ,
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy, Therapeutic Advances in Respiratory Disease, vol.14, p.175346662092923, 2020. ,
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy, Therapeutic Advances in Respiratory Disease, vol.14, p.175346662092923, 2020. ,
A rare and fatal respiratory disease: bronchial Dieulafoy?s disease, Therapeutic Advances in Respiratory Disease, vol.14, p.175346662092923, 2020. ,
Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies, Airway Pharmacology and Treatment, 2017. ,
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies, The Lancet Respiratory Medicine, vol.6, issue.1, pp.51-64, 2018. ,
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial, The Lancet, vol.380, issue.9842, pp.651-659, 2012. ,
Weight-adjusted Intravenous Reslizumab Attenuates Airway Eosinophilia in Severe Asthmatics compared to 100 mg Subcutaneous Mepolizumab, Monitoring Airway Disease, 2017. ,
Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab, American Journal of Respiratory and Critical Care Medicine, vol.197, issue.1, pp.38-46, 2018. ,
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma, European Respiratory Journal, vol.52, issue.4, p.1800936, 2018. ,
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma, European Respiratory Journal, vol.52, issue.4, p.1800936, 2018. ,
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma, New England Journal of Medicine, vol.371, issue.13, pp.1198-1207, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01785638
, Glucocorticoids and Mepolizumab in Eosinophilic Asthma, New England Journal of Medicine, vol.371, issue.25, pp.2433-2434, 2014.
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme, European Respiratory Journal, vol.55, issue.6, p.1902345, 2020. ,
Les citoyens et les me?dias, 2006. ,
Faut-il réaliser un suivi systématique par IRM chez les patients sous traitement de fond ?, Revue Neurologique, vol.169, p.A213, 2013. ,
Compte rendu du colloque portant sur «l?intervention du juge dans le contrat», Europäisches Privatrecht in Vielfalt geeint - Droit privé européen: l'unité dans la diversité ,
, Taux de mortalité infantile, 2013.
, La croissance annuelle de la formation brute de capital fixe est inférieure au niveau de 2010 pour un tiers environ des pays de l?OCDE, 2020.
L?estomac est-il un critère de qualité majeur dans la coupe du périmètre abdominal ? Audit auprès de 3 opérateurs, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, vol.45, issue.5, pp.484-489, 2016. ,
, Graphique 13.4. La croissance annuelle de la formation brute de capital fixe est inférieure au niveau de 2010 pour un tiers environ des pays de l?OCDE
Prévention du suicide: un dépistage aux urgences est possible, La Presse Médicale, vol.35, issue.5, pp.743-744, 2006. ,
, Graphique 6.20. Proportion des répondants qui estiment que la criminalité est un problème majeur dans leur pays (%), 2015
Peut-on parler de musique noire ?, Volume !, issue.6 : 1-2, pp.171-175, 2008. ,
URL : https://hal.archives-ouvertes.fr/halshs-00335273
Les femmes travaillent quel que soit le prix, quel qu?en soit le prix, Genre et économie : un premier éclairage, pp.275-286 ,